The White House said Tuesday it did not expect a major shock to the nationwide vaccination program after US regulators recommended a pause in the use of Johnson & Johnson’s COVID-19 injections as they examine six cases of blood clots. rare. “This announcement will not have a significant impact on our vaccination plan,” Jeff Zients, the White House COVID-19 response coordinator, said in a statement.
JNJ from J&J, -1.25% single-shot vaccine makes up less than 5% of gun shots in the US So far, according to Zients. The Biden administration has secured sufficient doses of Pfizer’s PFizer, vaccine + 0.57% and Moderna‘s MRNA, vaccine + 7.49% for 300 million Americans, and has made more than 25 million doses of those products available each week during the last weeks, he said. additional. “This week we will make 28 million doses of these vaccines available,” Zients also said, referring to the injections from Pfizer and Moderna. “This is more than enough supply to continue the current vaccination rate of 3 million injections per day and meet the president’s goal of 200 million injections by his 100th day in office, and continue to reach all adults. who want to get vaccinated. “President Joe Biden echoed Zients in comments made later Tuesday, saying the United States has enough vaccine” for every lonely American. “Biden last month launched a new target for COVID-19 vaccines, going for 200. million arms shots for his 100th day in office, up from his initial goal of 100 million shots. Zients also said Tuesday that the White House is working with its state and federal partners to have anyone scheduled for a vaccine J&J is quickly rescheduled for a Pfizer or Modern vaccine. US stocks SPX, + 0.45% DJIA, -0.09% COMP, + 1.15% were trading mixed Tuesday after the temporary halt to the J&J jab. Now read: The Vaccine Program US COVID Faces Setback With J&J Jab As Experts Say No Cause For Alarm AND See: Johnson & Johnson Vaccine Pause: What To Know If You Got Or Scheduled The Injection